Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 06, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
On January 5, 2005, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 1,138 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on January 6, 2005.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Consequently, three directors (Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe) hold an interest in the shares held by the trust in the same manner as other employees.
Key Facts for Investor Verification
- 1,138 Ordinary Shares were transferred from the GSK Trust to employee plan participants on January 5, 2005.
- Directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe have an indirect interest in the GSK Trust shares.
- This filing does not contain financial results; investors should refer to Form 20-F for financial data.